• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Time And Sales Reporter
Editor's PickInvesting

Making Medicine Cost More Won’t Make America Healthy Again

by April 14, 2025
April 14, 2025

Jeffrey A. Singer

Medicine Pharmacy

Last week, President Donald Trump told a National Republican Congressional Committee audience that he intends to impose tariffs on pharmaceutical products entering the United States soon. Finished pharmaceutical products and active pharmaceutical ingredients (APIs) are not subject to the tariffs imposed last week. He hopes to “re-shore” pharmaceutical manufacturing. American patients, already facing declining health care access and rising health care costs, should brace for even greater challenges.

Approximately one-third of finished pharmaceutical products available in the United States are produced domestically. In 2024, the European Union (EU) exported $127 billion in pharmaceuticals to the US, its largest export to this country. Of this amount, $78.61 billion came from Ireland due to its favorable tax and regulatory environment and skilled workforce. In 2023, China exported $2.2 billion in pharmaceutical products to the US.

According to a report from Avalere Health, about 47 percent of APIs used to make medicines that Americans consume are imported from other countries. The EU is the largest foreign source of APIs produced for the US market, accounting for 26 percent, with India in second place at 18 percent. According to the FDA’s Center for Drug Evaluation and Research, API manufacturers operate 13 percent of their facilities in China, 28 percent in the United States, and 59 percent in other countries around the world. One recent study found that 90 percent of generic drugs rely on imported APIs. A 2022 report from the Food and Drug Administration’s Office of Generic Drugs estimated that 91 percent of all prescriptions filled by US pharmacies are filled as generics.

Surveys reveal that people are quite worried about the high prices of prescription drugs. A recent Kaiser Family Foundation (KFF) poll indicated that most Americans believe prescription medicines are too expensive, with 30 percent reporting difficulties in affording them. Trump’s tariffs on finished pharmaceuticals and APIs will raise the cost of most medications.

Pharmaceutical companies can shift the cost of tariffs to American taxpayers by increasing Medicare, Medicaid, and the Veterans Affairs health systems charges. The irony is that taxpayers would offset any revenue gained from the tariffs through these expenditures.

However, in many instances, pharmaceutical companies will find it more difficult to pass the costs to consumers. Drug manufacturers negotiate prices with third-party payers, such as insurers, pharmaceutical benefits managers (PBMs), and certain government programs, often establishing fixed prices or rebates, which limits manufacturers’ ability to increase prices without renegotiating terms. Competition and payer contracts significantly restrict drug prices, so manufacturers may struggle to transfer tariff costs to consumers without jeopardizing contracts or market share.

Manufacturers might raise prices to offset higher costs, but insurers often absorb these increases instead of passing them on to consumers. Tariff-induced cost hikes could lead to higher patient co-pays and out-of-pocket expenses if insurers or PBMs adjust cost-sharing to protect their profit margins. Finally, insurers can pass on their increased costs through higher premiums.

Finally, pharmaceutical companies may have to absorb certain tariff-related costs that they cannot pass on to taxpayers, third-party payers, or consumers. This will lower their profits and leave companies with fewer resources for investing in research and development. Consequently, all of us will bear the cost of diminished pharmaceutical innovation. We will never know which next breakthrough was lost to diminished innovation.

In the end, tariffs on pharmaceuticals won’t just impact balance sheets—they will also affect patients. Whether through higher premiums, increased out-of-pocket costs, or fewer new treatments in the future, American health care consumers will bear the burden. These policies may sound tough on paper, but their real-world effects further strain an already pressured health care system and put lifesaving medications even further out of reach. If the goal is to make medicines more affordable and accessible, punishing the supply chain that delivers them is exactly the wrong approach.

previous post
Pete Marocco, mastermind behind dismantling of USAID projects, leaves State Department
next post
Voters widely oppose taxpayer-funded gender surgeries, revealing Democrat Party’s vulnerability: poll

Related Posts

Crypto Market Update: FalconX to Buy 21Shares, Senate...

October 23, 2025

Despatch of SPP Offer Documents

October 23, 2025

Lithium Market Update: Q3 2025 in Review

October 23, 2025

Gianni Kovacevic: Silver, Oil to Break US$100, but...

October 23, 2025

Apollo Silver

October 23, 2025

Chris Vermeulen: Gold Signaling “Massive” Equities Correction, My...

October 22, 2025







    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.




    Recent Posts

    • American missionary kidnapped in Niger by suspected Islamist militants, sources say

      October 23, 2025
    • Schumer blocks 12th GOP bid to reopen government as Trump says Democrats ‘lost the negotiation’

      October 23, 2025
    • Trump meets NATO’s Rutte amid canceled Putin meeting: ‘It didn’t feel right to me’

      October 23, 2025
    • FLASHBACK: Ted Cruz predicts ballooning Obamacare subsidies now at center of shutdown fight

      October 23, 2025
    • Sparks fly as Cuomo, Mamdani tear into each other during fiery debate: ‘Toxic energy’

      October 23, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 timeandsalesreporter.com | All Rights Reserved

    Time And Sales Reporter
    • World News
    • Politics
    • Stock
    • Investing
    • Editor’s Pick

    Read alsox

    Trump Orders Declassification of Remaining JFK, RFK, and...

    January 24, 2025

    Alvopetro Energy

    September 5, 2025

    The CEO in chief: How Trump is getting...

    August 15, 2025